Atara Biotherapeutics Inc (ATRA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.37+2.07%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ATRA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 52.2% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 112.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ATRA — CFO transition
Dated 2026-06-26
Chief Accounting Officer — Yanina Grant-Huerta: The departure of the Chief Accounting Officer and appointment of an interim chief financial officer indicate significant changes in management.
Why it matters: FDA approval could unlock a $31 million milestone and sales royalties for Atara. Another rejection would leave that path blocked.
Watch forThe FDA approves the tab-cel BLA for EBV+ PTLD and Atara reports the $31 million milestone is due.
Also watch forThe FDA issues another complete response letter or rejects the BLA.
Why it matters: The FDA agreed that the ALLELE study may support a new application. A filed BLA would move tab-cel toward FDA review and could trigger a $31 million payment to Atara.
Supportive ifPierre Fabre files the tab-cel BLA with more ALLELE patients, a longer follow-up, and added data.
Worry ifPierre Fabre delays the filing or says it cannot submit the planned updated data.
Why it matters: Lower spending supports Atara’s stated cash runway into mid-2027. A sharp rise could shorten that runway.
Watch forQuarterly costs and operating expenses stay at or below $5.4 million. This is near Q2 2026’s $5.35 million.
Also watch forQuarterly costs and operating expenses top $5.4 million for two quarters in a row.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$311 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $910 loss on $10,000 · 9.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,689 loss on $10,000 · 76.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.